OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	200
Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging	194
V/Q SPECT/CT in the Time of COVID-19: Changing the Order to Improve Safety Without Sacrificing Accuracy	180
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	111
Practicing Medicine in Wartime Ukraine	110
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	108
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	107
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	106
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	98
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	97
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma	94
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	90
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	87
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	86
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	85
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	82
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	81
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	75
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	73
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	70
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	66
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	64
Localized In Vivo Prodrug Activation Using Radionuclides	64
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	62
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	60

Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	59
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)	59
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities	59
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	57
Molecular Imaging Leadership in Academia and Industry	55
Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer	53
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	52
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection	52
Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome	52
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	51
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?	51
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	49
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	49
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on¹⁸F-FDG PET/MRI and Machine Learning	48
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem	48
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	47
The Role of Molecular Imaging in Precision Oncology	47
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer	47
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer	46
¹⁸F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol	46
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	45
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	44
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	44
Nanoparticle Diagnostics and Theranostics in the Clinic	43
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	43
Early-Phase¹⁸F-Florbetapir and¹⁸F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting	43
⁶⁸Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism	42
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	41
High-Resolution Silicon Photomultiplier Time-of-Flight Dedicated Head PET System for Clinical Brain Studies	41
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	40
Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies	40
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	40
Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline ¹⁸F-FDG PET/CT in Metastatic Melanoma	40
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer	39
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	39
Precision Medicine Clinical Trials	39
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	38
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	38
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	37
Perspectives on Cutting-Edge Clinical Trials	37
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	37
CD38-Targeted⁸⁹Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care	36
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy	36
First-in-Human Evaluation of Site-Specifically Labeled⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer	36
Feasibility of¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer	36
First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer	36
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council	36
An External, Independent Validation of anO-(2-[¹⁸F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma	35
Molecular Imaging, Radiochemistry, and Environmental Pollutants	35
Tumor Dose–Response Relationship of [¹³¹I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [¹²⁴I]MIBG PET	35

Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET	34
Comparison of ¹¹C-Pittsburgh Compound B and ¹⁸F-Flutemetamol White Matter Binding in PET	34
A Path to Qualification of PET/MRI Scanners for Multicenter Brain Imaging Studies: Evaluation of MRI-Based Attenuation Correction Methods Using a Patient Phantom	34
Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Pr	34
Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma	33
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins	33
Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ⁶⁸Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors	33
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling	33
Evaluating Bone Healing with [¹⁸F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment	32
Is It Too Soon to Know When It’s LATE?	32
Pretargeted Radioimmunotherapy of Ovarian Cancer with²²⁵Ac and an Internalizing Antibody	32
Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA: A Multicenter Retrospective Analysis	32
Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots	32
Bringing VISION to Nuclear Medicine: Accelerating Evidence and Changing Paradigms with Theranostics	32
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins	31
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study	31
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion	31
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET	31
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies	31
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results	30
Comparison of Baseline⁶⁸Ga-FAPI and¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibit	30
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma	30
Tau PET Imaging in Neurodegenerative Disorders	30
Green Nuclear Medicine and Radiotheranostics	29
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice	29
Not All Gatekeepers Are Theranostics	28
Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer	28
The Imperative for Comparative Studies in Nuclear Medicine: Elevating¹⁷⁷Lu-PSMA-617 in the Treatment Paradigm for mCRPC	28
The Rise of Molecular Image–Guided Robotic Surgery	28
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients	28
Posterior Cingulate Involvement Does Not Argue Against LATE	28
Identification of (R)-[¹⁸F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development	28
Potential of¹⁸⁸Re as an Alternative to¹⁷⁷Lu and Dosimetric Consequences	28
[⁶⁸Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis	27
⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study	27
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study	27
MIRD Pamphlet No. 29: MIRDy90—A⁹⁰Y Research Microsphere Dosimetry Tool	27
Radionuclide Imaging of the Gut–Brain Axis in Parkinson Disease	27
Molecular Imaging in Breast Cancer	27
Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?	26
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior²²³Ra (RALU Study)	26
Quantitative Brain Amyloid PET	26
Distinguishing Progression from Pseudoprogression in Glioblastoma Using¹⁸F-Fluciclovine PET	26
Tau PET Visual Reads: Research and Clinical Applications and Future Directions	26
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer	26
First-in-Human Study of¹⁸F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding	26
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy	26
Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease	26
Total Body PET – Will it Change Science and Practice?	26
Modeling early radiation DNA damage occurring during [¹⁷⁷Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy	26
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective	26
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?	25
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	25
Diagnostic Potential of Supplemental Static and Dynamic⁶⁸Ga-FAPI-46 PET for Primary¹⁸F-FDG–Negative Pulmonary Lesions	25
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections	25
Amino Acid PET in Neurooncology	25
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy	24
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides	24
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas	24
Advancing Nuclear Medicine at the Multiomics Intersection	24
Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose	24
Detecting CXCR4 Expression in Meningioma on⁶⁸Ga-Pentixafor PET/MRI	24
How Many Theranostics Centers Will We Need in the United States?	24
Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination	24
Recent Evidence on Cardiac^99mTc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis	24
Future Directions in Molecular Imaging of Neurodegenerative Disorders	23
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [¹⁸F]FDG PET/CT and¹³¹I Posttreatment Scanning	23
Tracking Innate Immune Activation in a Mouse Model of Parkinson’s Disease Using TREM1 and TSPO PET Tracers	23
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy	23
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy	23
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders	23
⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space	23
Association of Free-to-Total PSA Ratio and¹⁸F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Si	23
¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy	23
[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy	23
Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	23
Delayed Imaging Improves Lesion Detectability in [^99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer	23
Safety, Dosimetry, and Feasibility of [⁶⁸Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer	22
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent	22
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy	22

China’s Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact	22
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists	22
^99mTc-MIP-1404 SPECT/CT Companion Diagnostic for¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	22
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	22
Utility of⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on⁶⁸Ga-PSMA-11 PET/CT	22
Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW	22
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy	22
Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer	22
The Will Rogers Phenomenon and PSMA PET/CT	21
[⁶⁸Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria	21
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy	21
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET	21
A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor–Mediated Microglia Depletion in Experimental Stroke	21
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with¹⁶¹Tb and¹⁷⁷Lu: A Comparative Study	21
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	21
Total-Body ¹⁸F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations	21
Stakeholders of Theranostics	21
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for¹⁶¹Tb Compared with¹⁷⁷Lu with a Higher Dose Response for [¹⁶	21
Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial	21
⁶⁸Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression	21
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy	20
The Annual Journal Impact Factor Saga	20
Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies	20
[¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lu	20
Theranostic Digital Twins: An Indispensable Prerequisite for Personalized Cancer Care	20
Advancing Tomorrow’s Cancer Medicines	20
An ⁸⁹Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients	20
Design, Preclinical Evaluation, and Clinical Translation of⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma	20
The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?	20
Reply: Dosimetry in Radiopharmaceutical Therapy	20
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸F-rhPSMA-7.3 PET/CT in patients with prostate cancer	19
¹⁸F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors	19
Detection of additional primary neoplasms on ¹⁸F-Fluciclovine PET/CT in patients with primary prostate cancer	19
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis	19
Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer	19
Antihormonal-Treatment Status Affects⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer	19
Effect of Acute Hypoxia Exposure on the Availability of A₁Adenosine Receptors and Perfusion in the Human Brain	19
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard	18
Changes in Management After ¹⁸F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes	18
⁶¹Cu-Labeled Radiotracers: Alternative or Choice?	18
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer	18
Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview	18
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)	18
Immunohistochemical FAP Expression Reflects⁶⁸Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma	18
ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?	18
Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model	18
Differences in Fibroinflammatory Activity Shown on⁶⁸Ga-FAPI-04 and¹⁸F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease	18
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials	18
SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury	18
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE	18
A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer	18
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up	18
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy	18
Virtual Biopsy: Just an AI Software or a Medical Procedure?	18
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	17
Advancing Clinical Trial Innovation in Pancreatic Cancer	17
An¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy	17
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice	17
2024 SNMMI Highlights Lecture: General Clinical Specialties	17
From Scientist to Analyst to Strategist	17
Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)	17
The Future of Nuclear Medicine in the United States	17
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	17
Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor	17
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	17
Is Routine Dosimetry Really Happening?	17
Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia	17
Molecular Imaging of Pulmonary Fibrosis	17
Total-Body Parametric Imaging Using Relative Patlak Plot	17
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting	17
Advancing Nuclear Medicine in Australia over 3 Decades	17
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	17
Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET	17
Imaging of the Aging Human Brain	17
Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study	17
Whole-Body PET Imaging in Humans Shows That¹¹C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs	16
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for⁸⁹Zr-Trastuzumab	16
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM	16
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI	16
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data	16
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients	16
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?	16
Biodistribution, Dosimetry, and Pharmacokinetics of⁶⁸Ga-CBP8: A Type I Collagen–Targeted PET Probe	16
Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis	16
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	16
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	16
Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma	16
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma	16
[¹⁷⁷Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement	16
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	16
Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future	16
Exploring Vessel Wall Biology In Vivo by Ultrasensitive Total-Body PET	16
Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease	16
Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention	16
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	16